Greif (GEF) Q3 Earnings: Stock Likely to Beat Estimates?
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:19AM CDT
Greif (GEF) is slated to report third-quarter 2016 results on Aug 31.
CECE: 10.99 (-0.32), CDXS: 4.17 (-0.13), GEF: 42.63 (-0.37), AOS: 96.48 (-0.36)
How Codexis (CDXS) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:37AM CDT
Codexis is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
CDXS: 4.17 (-0.13)
Codexis Reports Financial Results for the Second Quarter of 2016
GlobeNewswire - Tue Aug 09, 3:05PM CDT
Net income reaches $2.2 million; revenues of $16.0 million include milestone payments from GSK and a major biopharmaceutical company, and 62% growth in core biocatalyst product sales
CDXS: 4.17 (-0.13)
Industrial Stocks' Aug 9 Earnings Preview: LABL, CDXS & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 7:07AM CDT
What's in Store for 4 Industrial Stocks, LABL, CDXS, ASCMA, HWCC, for Apr-Jun '16 Quarter?
HWCC: 5.95 (unch), LABL: 66.83 (+0.10), CDXS: 4.17 (-0.13), ASCMA: 23.21 (-1.38)
Codexis to Hold 2016 Second Quarter Conference Call on August 9
GlobeNewswire - Tue Aug 02, 6:00AM CDT
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report second quarter 2016 financial results after market close on Tuesday, August 9, 2016. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial results and provide a company update.
CDXS: 4.17 (-0.13)
Codexis Completes Obligations Under Research and Development Agreement with Leading Biopharmaceutical Company
GlobeNewswire - Thu Jul 28, 6:00AM CDT
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the successful completion of its obligations under a collaborative research and development agreement with a leading global biopharmaceutical company. Under the agreement, Codexis employed its CodeEvolver(R) protein engineering platform technology to develop a novel enzyme for use in its partner's preclinical therapeutic development program.
CDXS: 4.17 (-0.13)
Codexis to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 2:00 p.m. Eastern time (11:00 a.m. Pacific time). The conference is being held in New York City.
CDXS: 4.17 (-0.13)
Codexis to Present at Upcoming Investment Conferences
GlobeNewswire - Wed May 18, 6:00AM CDT
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:
CDXS: 4.17 (-0.13)
Codexis reports 1Q loss
Automated Insights - Mon May 09, 4:58PM CDT
REDWOOD, Calif. (AP) _ Codexis Inc. (CDXS) on Monday reported a loss of $7 million in its first quarter.
CDXS: 4.17 (-0.13)
Codexis Reports Financial Results for the First Quarter of 2016
GlobeNewswire - Mon May 09, 3:05PM CDT
Revenues increase 18% to $8.0 million on significant growth in core biocatalyst R&D revenues and product sales
CDXS: 4.17 (-0.13)
Codexis to Hold 2016 First Quarter Conference Call on May 9
GlobeNewswire - Mon May 02, 3:05PM CDT
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2016 financial results after market close on Monday, May 9, 2016. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial results and provide a company update.
CDXS: 4.17 (-0.13)
AptarGroup Tops Q4 Earnings, Shares Down on Revenue Fall
Zacks Equity Research - Zacks Investment Research - Mon Feb 08, 9:10AM CST
AptarGroup, Inc.'s (ATR) Q4 earnings beat the Zacks Consensus Estimate, but shares dipped on the top-line decline.
AIN: 42.33 (-0.60), CDXS: 4.17 (-0.13), MINI: 29.90 (-0.06), ATR: 77.98 (-0.71)
Avery Dennison Beats on Q4 Earnings, Initiates 2016 View
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 11:04AM CST
Avery Dennison Corporation's (AVY) Q4 earnings of 85 cents per share beat the Zacks Consensus Estimate by 9%.
AIN: 42.33 (-0.60), CDXS: 4.17 (-0.13), AVY: 77.44 (-0.06), ASTE: 58.79 (-1.19)
Proto Labs (PRLB) to Report Q4 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 1:20PM CST
Proto Labs, Inc. (PRLB) is scheduled to report fourth-quarter 2015 results on Feb 4, before the market opens. The Zacks Consensus Estimate for the quarter is pegged at 44 cents per share.
UNF: 128.39 (-0.15), SEE: 47.13 (+0.03), PRLB: 54.72 (-4.74), CDXS: 4.17 (-0.13)
Xylem (XYL) to Report Q4 Earnings: Will it Surprise Investors?
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 12:50PM CST
Xylem Inc. (XYL) is scheduled to report fourth-quarter 2015 results before the opening bell on Feb 4, 2016.
XYL: 50.86 (-0.11), SEE: 47.13 (+0.03), CDXS: 4.17 (-0.13), BRC: 33.49 (-0.26)
Bemis (BMS) Beats on Q4 Earnings, Issues Upbeat 2016 View
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 11:20AM CST
Bemis Company, Inc. (BMS) Q4 earnings of 60 cents per share beat the Zacks Consensus Estimate by a penny.
BGG: 19.01 (-0.14), CDXS: 4.17 (-0.13), ASTE: 58.79 (-1.19), BMS: 52.60 (+0.10)
Pentair (PNR): Another Earnings Beat in the Cards?
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 3:35PM CST
Pentair plc (PNR) is slated to report fourth-quarter 2015 results on Feb 2, before the opening bell.
SEE: 47.13 (+0.03), CDXS: 4.17 (-0.13), PNR: 64.05 (-0.11), AOS: 96.48 (-0.36)